Jensen: the longevity field turns aging mechanisms into startups faster than it finds new ones

Epigenetic clocks, senescent cells, the mTOR pathway, reprogramming, young blood. Between the early 2000s and 2016 (the rough boundary: Ocampo's paper on partial reprogramming), the aging field assembled a set of powerful ideas about the mechanisms of aging. Startups and clinical programs now draw on these ideas, but a new generation of fundamental researchers, Jensen argues, has not kept pace.

On 27 June, Martin Borch Jensen, chief scientific officer of Gordian Biotechnology and founder of Norn Group, wrote on X that the longevity field is too focused on translation: companies, drugs, biomarkers, human trials. Fundamental aging research, in his view, needs more support.

Jensen knows both sides. Gordian looks for therapies for age-related diseases in living animals: applied work. His nonprofit, Norn Group, has distributed more than $34 million through Impetus Grants across 145 projects, funding ideas too early for companies and too risky for conventional grants. In May, he warned that money for biological AI could flow into molecules and cells while leaving aging therapies without data on organs, organisms, and humans. His June post goes deeper: the field first needs people who discover new mechanisms of aging. Data and models come after.

Large new funding sources pull in the same direction. ARPA-H, the U.S. agency for high-risk medical programs, wants through its PROSPR program to measure aging outcomes in three years instead of decades. The FAST initiative inside PROSPR mines already-completed clinical trials for aging biomarkers to speed up future therapy testing. A candidate, a biomarker, Phase I, a partnership, a company exit: where the next step is clear, money and talent follow.

Calico, Alphabet's aging-biology company, together with startups and venture funds, showed investors that aging has concrete targets and a path to the clinic. This week Calico dropped from first to 26th in the Eternal Search company ratings.

If nothing changes, applied programs will cycle through the same targets in a few years: mTOR, senescence, NAD metabolism, reprogramming. The clinic tests hypotheses that fundamental biology has had time to produce, and someone has to keep replenishing the supply.

Gordian itself embodies this tension: an applied biotech company whose chief scientific officer founded a separate nonprofit to distribute grants for fundamental research.

Open the Gordian Biotechnology page on Eternal Search

Sources
x.com
t.me
norn.group
t.me